Skip to main content
. 2019 Apr 27;3(2):pkz026. doi: 10.1093/jncics/pkz026

Table 3.

Circulating tumor cells in adjuvant therapy: main published studies and meta-analysis*

References No. of patients Stage Blood screened, mL Detection rate, %
 Prognostic impact
Pre. ACT Post. ACT DFS HR (95% CI) OS HR (95% CI)
Studies
Krishnamurthy et al. (33) (2010) 92 I–III 7.5 31 — — —
Franken et al. (31) (2012) 404 I–III 7.5 18 —

  • Yes

  • 1.6 (0.83 to 3.19)

 to
Lucci et al. (32) (2012) 302 I–III 7.5 24 —

  • Yes

  • 4.62 (1.79 to 11.9)

  • Yes

  • 4.04 (1.28 to 12.8)
Karhade et al. (30) (2014) 113 I–III (triple-negative) 7.5 25 —

  • Yes

  • 8.30 (2.61 to 26.4)

  • Yes

  • 7.19 (1.98 to 26.1)
Rack et al. (34) (2014) 2026 I–III 30 21 22

  • Yes

  • 2.11 (1.49 to 2.99)

  • Yes

  • 2.18 (1.32 to 3.59)
Van Dalum et al. (29) (2015) 403 I–III 30 19 15

  • Yes

  • (n.a.)

  • Yes

  • (n.a.)
Pooled-analysis
Janni et al. (12) (2016) 3173 I–III 7.5 20 —

  • Yes

  • 1.82 (1.47 to 2.26)

  • Yes

  • 1.97 (1.51 to 2.59)
*

ACT = adjuvant chemotherapy; CI = confidence interval; DFS = disease-free survival; CI = confidence interval; HR = hazard ratio; n.a. = not available; OS = overall survival; pts = patients.